Arvinas, Inc.

NasdaqGS:ARVN Stock Report

Market Cap: US$753.4m

Arvinas Management

Management criteria checks 1/4

Arvinas' CEO is John Houston, appointed in Sep 2017, has a tenure of 8.25 years. total yearly compensation is $12.75M, comprised of 5.4% salary and 94.6% bonuses, including company stock and options. directly owns 1.42% of the company’s shares, worth $10.70M. The average tenure of the management team and the board of directors is 1.9 years and 6.2 years respectively.

Key information

John Houston

Chief executive officer

US$12.7m

Total compensation

CEO salary percentage5.37%
CEO tenure8.3yrs
CEO ownership1.4%
Management average tenure1.9yrs
Board average tenure6.2yrs

Recent management updates

Recent updates

Arvinas: Approvable, But Asset Looks Mediocre, Initiating With A Hold Rating

Nov 24

Improved Revenues Required Before Arvinas, Inc. (NASDAQ:ARVN) Stock's 26% Jump Looks Justified

Sep 09
Improved Revenues Required Before Arvinas, Inc. (NASDAQ:ARVN) Stock's 26% Jump Looks Justified

We're Not Very Worried About Arvinas' (NASDAQ:ARVN) Cash Burn Rate

Jun 01
We're Not Very Worried About Arvinas' (NASDAQ:ARVN) Cash Burn Rate

Arvinas, Inc.'s (NASDAQ:ARVN) Shares Bounce 37% But Its Business Still Trails The Industry

May 01
Arvinas, Inc.'s (NASDAQ:ARVN) Shares Bounce 37% But Its Business Still Trails The Industry
User avatar

Phase III And PROTAC Data Will Advance Pipeline Despite Hurdles

Successful trials and partnerships in oncology could support Arvinas' transition to commercial operations, driving growth and revenue potential.

Arvinas: Veritac-2 ITT Failure Confirms Limited Prospects

Mar 14

Arvinas, Inc. (NASDAQ:ARVN) Not Doing Enough For Some Investors As Its Shares Slump 56%

Mar 12
Arvinas, Inc. (NASDAQ:ARVN) Not Doing Enough For Some Investors As Its Shares Slump 56%

Arvinas' Vepdegestrant: Why The Data May Not Hold Up

Dec 25

Arvinas (NASDAQ:ARVN) Is In A Good Position To Deliver On Growth Plans

Dec 24
Arvinas (NASDAQ:ARVN) Is In A Good Position To Deliver On Growth Plans

Investors Still Waiting For A Pull Back In Arvinas, Inc. (NASDAQ:ARVN)

Nov 28
Investors Still Waiting For A Pull Back In Arvinas, Inc. (NASDAQ:ARVN)

Arvinas: Major Catalyst Ahead, But Its History Gives Me Pause

Oct 16

Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Aug 02
Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Arvinas: Hugely Important Data Catalyst Upcoming - Success May Prove Elusive

Jul 12

Here's Why We're Watching Arvinas' (NASDAQ:ARVN) Cash Burn Situation

Jun 27
Here's Why We're Watching Arvinas' (NASDAQ:ARVN) Cash Burn Situation

Arvinas: Behind The Huge Rally

Mar 03

What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You

Feb 25
What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You

News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts

Aug 13
News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts

There's Reason For Concern Over Arvinas, Inc.'s (NASDAQ:ARVN) Price

May 05
There's Reason For Concern Over Arvinas, Inc.'s (NASDAQ:ARVN) Price

CEO Compensation Analysis

How has John Houston's remuneration changed compared to Arvinas's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$58m

Jun 30 2025n/an/a

-US$73m

Mar 31 2025n/an/a

-US$47m

Dec 31 2024US$13mUS$684k

-US$199m

Sep 30 2024n/an/a

-US$309m

Jun 30 2024n/an/a

-US$323m

Mar 31 2024n/an/a

-US$355m

Dec 31 2023US$8mUS$658k

-US$367m

Sep 30 2023n/an/a

-US$295m

Jun 30 2023n/an/a

-US$298m

Mar 31 2023n/an/a

-US$301m

Dec 31 2022US$10mUS$632k

-US$282m

Sep 30 2022n/an/a

-US$253m

Jun 30 2022n/an/a

-US$233m

Mar 31 2022n/an/a

-US$213m

Dec 31 2021US$13mUS$584k

-US$191m

Sep 30 2021n/an/a

-US$180m

Jun 30 2021n/an/a

-US$164m

Mar 31 2021n/an/a

-US$139m

Dec 31 2020US$8mUS$564k

-US$119m

Sep 30 2020n/an/a

-US$99m

Jun 30 2020n/an/a

-US$86m

Mar 31 2020n/an/a

-US$78m

Dec 31 2019US$5mUS$528k

-US$70m

Compensation vs Market: John's total compensation ($USD12.75M) is above average for companies of similar size in the US market ($USD3.49M).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.

CEO

John Houston (65 yo)

8.3yrs
Tenure
US$12,746,981
Compensation

Dr. John G. Houston, Ph.D. serves as Independent Director at NextCure, Inc. since September 10, 2020. He has been President, Chief Executive Officer and Director of Arvinas, Inc. since September 20, 2017 a...

Leadership Team

NamePositionTenureCompensationOwnership
John Houston
Chairperson8.3yrsUS$12.75m1.42%
$ 10.7m
Andrew Saik
CFO & Treasurer1.5yrsUS$3.72m0.015%
$ 113.2k
Angela Cacace
Chief Scientific Officer1.5yrsUS$2.97m0.037%
$ 279.7k
Randy Teel
Chief Business Officer1.7yrsUS$3.78m0.030%
$ 227.7k
Noah Berkowitz
Chief Medical Officer1.8yrsUS$6.10m0.011%
$ 84.5k
David Loomis
VP & Chief Accounting Officerno datano data0.0089%
$ 67.2k
Jeff Boyle
Vice President of Investor Relations4.9yrsno datano data
Jared Freedberg
General Counsel & Corporate Secretary1.9yrsno datano data
Steve Weiss
Senior VP & Chief Human Resources Officerno datano datano data
Lisa Sinclair
Senior Vice President of Corporate Operations3.3yrsno datano data
Paul McInulty
Senior Vice President of Regulatory Affairs3.2yrsno datano data
Alexander Santini
Interim Chief Commercial Officer & Senior VP of Global and U.S. Market Accessno datano datano data
1.9yrs
Average Tenure
56yo
Average Age

Experienced Management: ARVN's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
John Houston
Chairperson8.3yrsUS$12.75m1.42%
$ 10.7m
Edward Kennedy
Independent Director7.4yrsUS$451.53k0.082%
$ 618.7k
Lillian Siu
Member of Scientific Advisory Board6.2yrsno datano data
Leslie Norwalk
Independent Director6.4yrsUS$451.53k0.016%
$ 117.5k
Briggs Duncan W. Morrison
Lead Independent Director7.5yrsUS$480.39k0.093%
$ 703.8k
Laurie Smaldone Alsup
Independent Director6.1yrsUS$456.53k0.016%
$ 117.5k
Adam Boxer
Member of Scientific Advisory Board6.2yrsno datano data
Lennart Mucke
Member of Scientific Advisory Board6.2yrsno datano data
Bradley Hyman
Member of Scientific Advisory Board3.8yrsno datano data
Benjamin Neel
Member of Scientific Advisory Board6.2yrsno datano data
Linda Bain
Independent Director5.5yrsUS$461.53k0.016%
$ 117.5k
Ian Taylor
Chairman of Scientific Advisory Boardless than a yearUS$4.22m0.18%
$ 1.4m
6.2yrs
Average Tenure
64yo
Average Age

Experienced Board: ARVN's board of directors are considered experienced (6.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/31 13:20
End of Day Share Price 2025/12/31 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Arvinas, Inc. is covered by 28 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Etzer DaroutBarclays
Tazeen AhmadBofA Global Research